1.00
price down icon5.66%   -0.06
after-market Handel nachbörslich: 1.10 0.10 +10.00%
loading
Schlusskurs vom Vortag:
$1.06
Offen:
$1.02
24-Stunden-Volumen:
1.10M
Relative Volume:
0.89
Marktkapitalisierung:
$71.13M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-192.96M
KGV:
-0.303
EPS:
-3.3
Netto-Cashflow:
$-167.04M
1W Leistung:
-18.70%
1M Leistung:
-30.56%
6M Leistung:
-51.46%
1J Leistung:
-80.69%
1-Tages-Spanne:
Value
$0.99
$1.06
1-Wochen-Bereich:
Value
$0.99
$1.235
52-Wochen-Spanne:
Value
$0.99
$5.66

Ventyx Biosciences Inc Stock (VTYX) Company Profile

Name
Firmenname
Ventyx Biosciences Inc
Name
Telefon
(858) 945-2393
Name
Adresse
12790 EL CAMINO REAL, SUITE 200, SAN DIEGO
Name
Mitarbeiter
0
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-04
Name
Neueste SEC-Einreichungen
Name
VTYX's Discussions on Twitter

Vergleichen Sie VTYX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
VTYX
Ventyx Biosciences Inc
1.00 71.13M 0 -192.96M -167.04M -3.30
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.01 124.29B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.64 66.76B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
590.06 35.99B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
262.16 33.93B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
264.32 28.47B 3.81B -644.79M -669.77M -6.24

Ventyx Biosciences Inc Stock (VTYX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-03-12 Hochstufung Oppenheimer Perform → Outperform
2024-03-12 Hochstufung Wells Fargo Equal Weight → Overweight
2023-11-07 Herabstufung H.C. Wainwright Buy → Neutral
2023-11-07 Herabstufung Morgan Stanley Overweight → Equal-Weight
2023-11-07 Herabstufung Oppenheimer Outperform → Perform
2023-11-07 Herabstufung Stifel Buy → Hold
2023-11-07 Herabstufung Wells Fargo Overweight → Equal Weight
2023-06-14 Fortgesetzt Credit Suisse Outperform
2023-03-21 Eingeleitet Wells Fargo Overweight
2022-12-19 Eingeleitet Goldman Buy
2022-11-17 Eingeleitet Morgan Stanley Overweight
2022-09-07 Eingeleitet Stifel Buy
2022-09-01 Eingeleitet H.C. Wainwright Buy
2022-05-09 Eingeleitet Credit Suisse Outperform
2022-03-31 Eingeleitet Canaccord Genuity Buy
2022-02-01 Eingeleitet Oppenheimer Outperform
2021-11-15 Eingeleitet Jefferies Buy
2021-11-15 Eingeleitet Piper Sandler Overweight
Alle ansehen

Ventyx Biosciences Inc Aktie (VTYX) Neueste Nachrichten

pulisher
04:44 AM

Ventyx Biosciences chief scientific officer John Nuss sells $2,019 in shares - Investing.com India

04:44 AM
pulisher
Apr 02, 2025

VTYX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Ventyx Biosciences, Inc. Investors Can Join the Class Action Lawsuit! - ACCESS Newswire

Apr 02, 2025
pulisher
Apr 02, 2025

Shareholders that lost money on Ventyx Biosciences, Inc.(VTYX) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire

Apr 02, 2025
pulisher
Apr 02, 2025

Stock Traders Purchase Large Volume of Call Options on Ventyx Biosciences (NASDAQ:VTYX) - Defense World

Apr 02, 2025
pulisher
Apr 01, 2025

Ventyx boosts advisory board with top scientists By Investing.com - Investing.com South Africa

Apr 01, 2025
pulisher
Apr 01, 2025

Ventyx boosts advisory board with top scientists - Investing.com

Apr 01, 2025
pulisher
Apr 01, 2025

Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts - GlobeNewswire

Apr 01, 2025
pulisher
Mar 31, 2025

Insiders' US$1.26m Investments In Red Following Ventyx Biosciences' US$11m Dip In Market Value - simplywall.st

Mar 31, 2025
pulisher
Mar 28, 2025

Ventyx Biosciences stock hits 52-week low at $1.21 amid market challenges - Investing.com

Mar 28, 2025
pulisher
Mar 21, 2025

Ventyx Biosciences stock hits 52-week low at $1.28 amid market challenges - Investing.com Australia

Mar 21, 2025
pulisher
Mar 15, 2025

Ventyx Biosciences Faces Supply Chain Risks Amidst U.S.-China Tensions and Regulatory Challenges - MSN

Mar 15, 2025
pulisher
Mar 11, 2025

Ventyx Biosciences stock hits 52-week low at $1.37 amid market challenges - Investing.com Australia

Mar 11, 2025
pulisher
Mar 10, 2025

Rhumbline Advisers Acquires 40,813 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World

Mar 10, 2025
pulisher
Mar 08, 2025

Ventyx Biosciences, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before April 30, 2024 to Discuss Your Rights – VTYX - ACCESS Newswire

Mar 08, 2025
pulisher
Mar 04, 2025

Ventyx Biosciences Reports 2024 Financial Results and Progress - TipRanks

Mar 04, 2025
pulisher
Mar 04, 2025

Levi & Korsinsky Notifies Shareholders of Ventyx Biosciences, Inc.(VTYX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire

Mar 04, 2025
pulisher
Mar 03, 2025

Ventyx Biosciences stock hits 52-week low at $1.41 amid market challenges - Investing.com India

Mar 03, 2025
pulisher
Mar 03, 2025

Ventyx Biosciences stock hits 52-week low at $1.41 amid market challenges By Investing.com - Investing.com South Africa

Mar 03, 2025
pulisher
Mar 03, 2025

FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses of $100,000 to Contact the Firm - ACCESS Newswire

Mar 03, 2025
pulisher
Mar 03, 2025

Class Action Filed Against Ventyx Biosciences, Inc. (VTYX)April 30, 2024 Deadline to JoinContact Levi & Korsinsky - ACCESS Newswire

Mar 03, 2025
pulisher
Mar 03, 2025

Ventyx Biosciences, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationVTYX - ACCESS Newswire

Mar 03, 2025
pulisher
Mar 02, 2025

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses of $100,000 to Contact the Firm - ACCESS Newswire

Mar 02, 2025
pulisher
Mar 02, 2025

FINAL DEADLINE TUESDAY: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses to Contact the Firm - ACCESS Newswire

Mar 02, 2025
pulisher
Feb 28, 2025

Ventyx Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Feb 28, 2025
pulisher
Feb 28, 2025

VTYX SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Ventyx Biosciences, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire

Feb 28, 2025
pulisher
Feb 27, 2025

Ventyx Biosciences reports Q4 EPS (41c), consensus (55c) - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

VTYXVentyx Biosciences, Inc. Latest Stock News & Market Updates - Stock Titan

Feb 27, 2025
pulisher
Feb 27, 2025

Levi & Korsinsky Notifies Shareholders of Ventyx Biosciences, Inc. (VTYX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 27, 2025

Ventyx Biosciences Reports Fourth Quarter and Full Year - GlobeNewswire

Feb 27, 2025
pulisher
Feb 27, 2025

Can Ventyx's $252.9M Cash Cushion and 3 Upcoming Trial Readouts Excite Biotech Investors? - StockTitan

Feb 27, 2025
pulisher
Feb 27, 2025

Ventyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Corporate Progress - Yahoo Finance

Feb 27, 2025
pulisher
Feb 24, 2025

Ventyx Biosciences stock hits 52-week low at $1.57 By Investing.com - Investing.com Australia

Feb 24, 2025
pulisher
Feb 24, 2025

Ventyx Biosciences stock hits 52-week low at $1.57 - Investing.com India

Feb 24, 2025
pulisher
Feb 23, 2025

Investors who lost money on Ventyx Biosciences, Inc.(VTYX) should contact Levi & Korsinsky about pending Class ActionVTYX - ACCESS Newswire

Feb 23, 2025
pulisher
Feb 23, 2025

Ventyx Biosciences (VTYX) to Release Earnings on Tuesday - Defense World

Feb 23, 2025
pulisher
Feb 21, 2025

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses of $100,000 to Contact the Firm - ACCESS Newswire

Feb 21, 2025
pulisher
Feb 21, 2025

Ventyx Biosciences Inc expected to post a loss of 54 cents a shareEarnings Preview - TradingView

Feb 21, 2025
pulisher
Feb 19, 2025

VTYX SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Ventyx Biosciences, Inc. Investors Can Join the Class Action Lawsuit! - ACCESS Newswire

Feb 19, 2025
pulisher
Feb 18, 2025

Ventyx Biosciences Announces Presentation of Data from the - GlobeNewswire

Feb 18, 2025
pulisher
Feb 18, 2025

Ventyx Biosciences’ VTX958 shows efficacy in Crohn’s Disease - TipRanks

Feb 18, 2025
pulisher
Feb 18, 2025

Ventyx reports mixed results in Crohn's disease trial By Investing.com - Investing.com Australia

Feb 18, 2025
pulisher
Feb 18, 2025

Ventyx reports mixed results in Crohn's disease trial - Investing.com India

Feb 18, 2025
pulisher
Feb 18, 2025

Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 - The Bakersfield Californian

Feb 18, 2025
pulisher
Feb 18, 2025

Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn’s Disease at ECCO 2025 - Yahoo Finance

Feb 18, 2025
pulisher
Feb 15, 2025

SG Americas Securities LLC Cuts Stake in Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World

Feb 15, 2025
pulisher
Feb 13, 2025

RSLS stock touches 52-week low at $2.57 amid market challenges - MSN

Feb 13, 2025

Finanzdaten der Ventyx Biosciences Inc-Aktie (VTYX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$67.48
price down icon 1.23%
$73.33
price down icon 0.15%
$31.79
price up icon 1.63%
$18.91
price down icon 7.58%
$92.01
price down icon 1.40%
biotechnology ONC
$264.32
price down icon 3.81%
Kapitalisierung:     |  Volumen (24h):